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Translational Research Speeds the Journey
from Lab Results to Clinical Outcomes
by Beth Notzon

W

hile basic science
researchers work
to unravel the
mysteries of the
causes of cancer and the cellular
and molecular mechanisms
involved, clinical researchers
study the effects of new drugs
and other treatments on patients
with cancer. For decades, efforts
have been under way to bring
the two ends of the research
spectrum together to translate
the findings in the laboratory
into increasingly more effective
cancer treatments. In recent
years, this collaborative spirit
has become so much a part of
the cancer research climate that
translational research is now
a byword of cancer research.
(Continued on next page)

Dr. Robert C. Bast, Jr., vice president
of the Office of Translational Research,
oversees all translational research conducted
at M. D. Anderson.
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Translational Research Speeds the Journey
(Continued from page 1)

“Translational research is really
about trying to bring together the
progress we’re making in the laboratory
with the progress we’re making in the
clinic.” This is how Robert C. Bast, Jr.,
M.D., vice president of the Office of
Translational Research at The University of Texas M. D. Anderson Cancer
Center, sums up the current situation
in cancer research. “If you look at
the progress that has occurred in the
laboratory in the past 10 to 20 years, our
knowledge has increased exponentially.
Our progress in the clinic—in detecting,
preventing, and curing cancer—has
increased steadily but is more linear,
more incremental.”
M. D. Anderson’s Office of Translational Research was created in 2000,
with Dr. Bast as its first head. This office
has as its chief responsibility coordinating and facilitating translational research
conducted at M. D. Anderson and
collaborating institutions—in effect
making sure that the right hand always
knows what the left hand is doing.
Dr. Bast is a veritable directory of
the translational research being done
at M. D. Anderson, and he can provide
a litany of names and research areas.
In some cases, very basic research can

have an impact on important clinical
problems. For example, Benoit
deCrombrugghe, M.D., identifies
genes that control bone formation
and destruction, which are especially
relevant to breast and prostate cancers
that metastasize to bone. Studies of
basic tumor immunology also are
leading to new treatments for cancer.
Several years ago, Eugenie Kleinerman,
M.D., translated observations of
immunostimulants in a mouse model
into a novel and effective treatment for
osteosarcoma in children. Yong Jun Liu,
M.D., Ph.D., an authority on antigenpresenting cells, recently arrived at
M. D. Anderson and is working to
develop vaccines for cancer. Jeffrey J.
Molldrem, M.D., has already developed
some of the first effective vaccines for
leukemia, and cancer vaccines are also
the focus of Patrick Hwu, M.D., and
Larry Kwak, M.D., Ph.D., who are
building a remarkable community of
researchers whose goal is to translate
immunologic insights into clinical
results.
Antiangiogenesis is a primary
research interest of Isaiah J. Fidler,
Ph.D., D.V.M. The aim of antiangiogenic research is to block tumor growth

Dr. Edward F. Jackson, an associate professor in the Department of Imaging Physics,
examines magnetic resonance data in a new high-field (3-Tesla) magnetic resonance suite.
Dr. Jackson is developing ways to noninvasively monitor microvascular changes using
magnetic resonance imaging methods.
2
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by starving it of blood-borne nutrients.
Michael O’Reilly, M.D., and Lee M.
Ellis, M.D., also work with laboratory
models to understand angiogenesis and
to develop novel methods for inhibiting
tumor growth. James L. Abbruzzese,
M.D., Roy Herbst, M.D., Ph.D., and
Christopher Logothetis, M.D., have
translated laboratory observations into
novel clinical trials of angiogenesis
inhibitors, alone and in combination
with cytotoxic drugs. Renata Pasqualini,
Ph.D., and Wadih Arap, M.D., Ph.D.,
are studying molecular “zip codes” on
the inner surface of tumor-associated
blood vessels that might be used to
deliver drugs and other agents selectively to cancers. At the same time,
researchers such as Edward F. Jackson,
Ph.D., and John D. Hazle, Ph.D.,
are working out ways to measure
angiogenesis using diagnostic imaging
methods, initially in animal models
and subsequently in patients. A recent
addition, Juri Gelovani, M.D., Ph.D.,
is developing a molecular imaging
method that can identify biochemical
changes in cancers before and after
treatment.
Gene therapy is the focus of research
for a large group at M. D. Anderson
that includes Michael Andreeff, M.D.,
Ph.D., Jack A. Roth, M.D., Gary
Clayman, M.D., and Mien-Chie Hung,
Ph.D. Other investigators, such as JeanPierre Issa, M.D., are devising ways to
reawaken the expression of silenced
genes that can inhibit cancer growth.
In cancer prevention, Scott M.
Lippman, M.D., and his colleagues are
testing several different drugs to protect
people against prostate, breast, and
colon cancer. Over the years, Waun Ki
Hong, M.D., and Reuben Lotan, Ph.D.,
have been at the forefront internationally in the study of retinoids to prevent
tobacco-initiated cancers. Molecular
epidemiologists, led by Margaret Spitz,
M.D., are identifying methods to assess
the risk of developing cancer, and
researchers such as Xifeng Wu, M.D.,
Ph.D., are making exciting discoveries
in the area of single-nucleotide polymorphisms, which offer promise as a
way to identify people in large popula-

“If you look at the progress that has occurred in the laboratory
in the past 10 to 20 years, our knowledge has increased exponentially.”
– Robert C. Bast, Jr., M.D., vice president, Office of Translational Research

tions at risk for certain cancers who
would benefit from cancer screening
and chemoprevention.
As these research interests illustrate,
translational research occurs at each
organ site. Dr. Bast himself heads up the
ovarian cancer Specialized Programs of
Research Excellence (SPORE) grant,
and he noted that SPORE grants are
“specifically translational research
grants.” Or, as the National Cancer
Institute Web site explains, the main
purpose of these grants is “to promote
interdisciplinary research and to speed
the bi-directional exchange between
basic and clinical science to move basic
research findings from the laboratory
to applied settings involving patients and
populations.” Eight other SPORE grants
awarded to M. D. Anderson are in the
areas of lung, head and neck, endometrial, bladder, pancreatic, and prostate
cancer; melanoma; and leukemia.

Another byword in cancer research
is targeted therapy. Translational
research is particularly feasible now
because of, as Dr. Bast explained, “the
new understanding of what causes
cancer in different individuals, which
relates to different combinations of
genetic events.” This understanding has
come primarily from the work of basic
research scientists. Until fairly recently,
the only effective way to treat cancer
was to destroy or eliminate the cancerous cell using surgery, radiation therapy,
and chemotherapy. These treatments
destroy not only cancerous cells but
also healthy cells, leading to the often
serious side effects that are a hallmark
of most traditional cancer treatments.
While these standard therapies will
continue to play an important role in
the treatment of patients with cancer,
they can be vastly aided in this process
by targeted therapy, which literally

targets the aberrant biochemical
pathways that actually cause the cancer.
Malignant cells become dependent on
only a few abnormal chemical signals for
their survival. Normal cells have many
different biochemical pathways that
ensure their survival. Therefore,
targeting only one pathway in malignant cells leaves normal cells unharmed.
Gordon Mills, M.D., Ph.D., has found
that inhibition of the PI3 kinase enzyme
can selectively kill ovarian cancer cells,
with tolerable toxicity to normal cells,
particularly when the inhibitor is used
in combination with a standard cytotoxic drug such as paclitaxel. This
approach promises to open up an
entirely new vista in cancer treatment.
As Dr. Bast explained with some
excitement, “It is now possible to
imagine designing a specific prescription
for each patient wherein you would
(Continued on page 4)
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Translational Research Speeds the Journey
(Continued from page 3)

treat just exactly those abnormalities
that occurred in their cancer.”
It may take a while for this particular dream to become a reality, but in
the meantime, translational research
is already making an important
difference in the lives of cancer
patients. A prime example of this is
imatinib mesylate (Gleevec), a drug
that has shown amazing promise in
the treatment of patients with chronic
myelogenous leukemia (CML). “This
is the poster child of translational
research,” Dr. Bast noted. The development of the drug began with the
finding that 99% of patients with
CML have a single type of molecular
abnormality in their white blood
cells—a chromosomal translocation
that results in the formation of an
aberrant Bcr-Abl fusion protein that
constantly activates Abl kinase,
which is ordinarily only intermittently
activated. The continuous activation
of the enzyme causes CML cells to
proliferate and survive.
“Ninety-eight percent of patients
in the chronic phase of CML respond
initially to Gleevec. About a third of
the patients will show a resolution in
molecular abnormalities. And it is
even possible to effectively treat
patients who lapse into blast crisis,”
Dr. Bast said. These results improve
dramatically the outlook for most
patients with CML.
According to Dr. Bast, translational
research is focusing on “identifying
new drugs, antibodies, or genes that
would either neutralize the oncogenes,
the ‘accelerators’ that turn on tumor
growth, or that would replace the
‘brakes’ on cell growth, the dysfunctional tumor suppressor genes. Targeted
therapy can also intervene in the
signaling pathways of cancer cells so
that the cancer cells would be stimulated to self-destruct, whereas normal
tissues would be spared.”
He went on to explain that translational research is not just a single
process. “You are talking about the
whole spectrum of cancer research,”
Dr. Bast said. “There is translational
research at all different sites—breast
4
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“Translational research
is really about trying to
bring together the
progress we’re making
in the laboratory
with the progress
we’re making
in the clinic.”
– Robert C. Bast, Jr., M.D.,
vice president,
Office of Translational Research

cancer, gastrointestinal cancer, lung
cancer, and prostate cancer. There is
also translational research in early
detection, diagnosis, prevention,
and treatment.”
Moreover, the process of translational research is not a one-way
street. Discoveries also travel from
the clinic to the laboratory in the form
of clinical observations, human tissue,
diagnostic images, and blood samples,
which researchers use to further unlock
the secrets of cancer. Prime examples of
this are studies of the cells from patients
with CML who have become resistant
to Gleevec, such as those being led at
M. D. Anderson by Moshe Talpaz,
M.D. Stanley Hamilton, M.D., has
developed a molecular monitoring
laboratory to study changes in signaling
within tissues from patients who have
received targeted therapies. A phase I
working group headed by Razelle
Kurzrock, M.D., Dr. Herbst, and Frank
Giles, M.D., is developing hypothesisdriven trials of new agents, and Dan
Karp, M.D., has established a 17-bed
Clinical and Translational Research
Unit to facilitate close observation and
frequent sampling of blood and tissue.
Regardless of whether the patient
is on the giving or receiving end,
participation in translational research
benefits everyone. ●
FOR MORE INFORMATION, contact
Dr. Bast at (713) 792-7743.

New Tests Coul
to Chemotherap
in Patients with
by Katie Prout Matias

I

ntensive research over
the past several years has
made breast cancer one of
the most well-understood
cancers and led to the development of several new drugs that
can prolong survival. Because
of these life-prolonging treatment
options, the mortality rate from
breast cancer has dropped about
2% each year since the late
1980s in both the United States
and Western Europe. However,
oncologists still have no good way
of determining which treatment is
best for an individual patient or
whether a patient will respond to
a particular treatment. This is
especially true for chemotherapy.

Several chemotherapy regimens
are available for patients with newly
diagnosed breast cancer, but no regimen
is effective in more than 50% to 60%
of patients. Therefore, each patient has
only about a 50% chance of benefiting
from any given treatment, and many
patients receive costly and toxic
treatments that do not work.
To solve the problem of determining
which chemotherapy regimen will work
best in a particular patient, a team of
researchers led by Lajos Pusztai, M.D.,
Ph.D., an assistant professor in the
Department of Breast Medical Oncology
at The University of Texas M. D.
Anderson Cancer Center, has set out to
develop a tumor gene–screening test to
predict the efficacy of chemotherapy
regimens. Fifteen percent to 30% of
patients with newly diagnosed breast
cancer have a complete pathologic
response to chemotherapy; that is, all
microscopic evidence of invasive tumor

uld One Day Predict Response
apy and Presence of Metastatic Disease
h Breast Cancer

To determine which chemotherapy regimen will work best in a particular patient, Dr. Lajos
Pusztai, an assistant professor in the Department of Breast Medical Oncology, is developing tumor gene–screening tests to predict the efficacy of chemotherapy regimens for patients
with newly diagnosed breast cancer. Here he holds a gene chip that can measure the presence
or absence of 20,000 genes per patient tissue sample; the information is converted to numbers
that represent the gene expression profile.
cells disappears. “These patients still
require surgery, but their long-term
outcome is very good, and most of these
individuals will be cured, regardless of how
aggressive their disease appeared before
starting chemotherapy,” said Dr. Pusztai.
The researchers in Dr. Pusztai’s team
took tumor tissue samples from more
than 80 patients newly diagnosed with
breast cancer and examined more than
20,000 genes in each specimen. The
patients were then given paclitaxel,
5-fluorouracil, doxorubicin, and
cyclophosphamide (T/FAC, a commonly prescribed regimen at M. D.
Anderson). Six months later, the
patients underwent cancer surgery and
pathologic analysis for response to the
chemotherapy, and the gene expression
profiles of patients who had a complete
response were compared with those
of patients who did not.

Analyzing the results from the first
24 patients, the researchers found a
profile of 74 genes that was associated
with complete response to chemotherapy. They incorporated these 74
genes into a mathematical algorithm
to create a test that was 75% accurate
and 50% sensitive in predicting who
among a second sample of 21 patients
would have a complete response to the
same chemotherapy regimen. Patients
whose tumors tested positive had a 75%
chance of having a complete response
to T/FAC. These results were presented
at the plenary session of the 2003
annual meeting of the American
Society of Clinical Oncology.
The researchers are now developing
a second-generation T/FAC response
predictor test based on a larger patient
sample, which they hope will be more
sensitive. They are also working on a

portfolio of similar gene profile–based
predictors for other commonly used
preoperative chemotherapy regimens.
“If these new predictive tests prove
similarly accurate and treatment regimen
specific, it will fundamentally change
how we select treatment,” said Dr.
Pusztai. “For example, if the predictor
test indicated that several options would
work equally well in a patient, her
physician could choose the cheapest,
shortest, and least toxic of those regimens. For patients in whom a complete
response is unlikely with any of the
current standard treatments, participation in a clinical trial with new drug
combinations may be the most beneficial. This would also help speed up drug
development because you could focus on
developing new drugs for people who do
not benefit from existing treatments.”
While Dr. Pusztai’s team is trying
to improve survival rates by predicting
who will respond favorably to chemotherapy regimens, other researchers at
M. D. Anderson are trying to predict
unfavorable outcomes.
Twenty percent to 30% of all women
with apparently localized breast cancer
will eventually die of metastatic disease.
To identify these patients, researchers
are using new blood tests to analyze
what may be early metastatic events:
cancer cells in the peripheral blood
and bone marrow.
According to Kelly Hunt, M.D., an
associate professor in the Department of
Surgical Oncology at M. D. Anderson,
circulating cancer cells are found in a
large number of patients with breast
cancer, even those with early-stage
disease. “What that tells me is that
these cancers are systemic from the
very beginning,” said Dr. Hunt.
Researchers want to determine how
the circulating cells differ from primary
tumor cells, whether they can grow
outside the primary tumor site, and their
effect on prognosis and treatment.
A 2000 German study found that bone
(Continued on page 6)
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New Tests Could One Day Predict Response
(Continued from page 5)

Dr. Massimo Cristofanilli, an associate professor in the Department of Breast Medical
Oncology, and Graciela Rodriguez, a graduate research assistant in the Department
of Hematopathology, analyze a patient’s blood sample. Dr. Cristofanilli is investigating
whether the presence of cancer cells in peripheral blood is a marker for poor prognosis in
patients with breast cancer.
marrow disease was a good indicator of
prognosis: Breast cancer was more likely
to recur in patients with cancer cells in
their bone marrow.
To build on this study, researchers
at M. D. Anderson are participating in
a multicenter American College of
Surgeons Oncology Group trial in which
bone marrow aspirations are being performed on patients with breast cancer
to test for circulating cancer cells. The
prognostic value of the presence of cancer
cells in the bone marrow is then compared
with that of sentinel lymph node biopsy to
determine whether bone marrow aspiration
could also be used as a prognostic tool.
“We’ve done well with breast cancer
treatment over the past few decades, but
there are still patients who fall through the
cracks and for whom the treatment fails,
so I think that we still need to refine the
way that we identify which patients need
which treatment,” said Dr. Hunt. “I see
bone marrow aspiration as one other way
of getting a closer look at that patient and
what’s going on with her disease.”
Bone marrow aspiration could also be
used to determine the efficacy of com6
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mon chemotherapy regimens. Massimo
Cristofanilli, M.D., an associate professor
in the Department of Breast Medical
Oncology at M. D. Anderson, is giving
preoperative chemotherapy to patients
with bone marrow disease and testing
their bone marrow to see whether the
chemotherapy reduced the number of
cancer cells.
Dr. Cristofanilli is also investigating
the significance of cancer cells in the
peripheral blood. In a study presented
at the 2003 annual meeting of the
American Association for Cancer
Research, he and a team of researchers
found that 24 of 41 patients with
untreated metastatic breast cancer
had cancer cells circulating in their
peripheral blood. The researchers then
correlated the number of circulating
cells, or “tumor load,” with treatment
response and survival.
“It was very clear that the presence
of cells and even the number of cells
could predict the outcome of the
patient. The patients who did not have
cells had a very good prognosis. If they
had cells, they had very short survival,”

said Dr. Cristofanilli. He pointed out
that even patients with slow-growing
estrogen receptor–positive tumors,
which are not considered to be very
aggressive, had poor survival rates if
they had circulating tumor cells.
“This is a very important point, I think,
because this may help clinicians decide
when to treat, when to treat aggressively, and when not to treat.”
The most important question to
ask, said Dr. Cristofanilli, is how the
circulating cells differ from the original
or primary tumor cells. The researchers
want to determine whether the circulating cells have a different gene expression
or microenvironment. Dr. Cristofanilli
also wants to determine if a correlation
exists between circulating tumor cells
and patient response to various treatment protocols.
“I think the big picture is that
clinicians want to be more aggressive
in trying to improve our understanding
of what a treatment does in patients,”
said Dr. Cristofanilli. “There have been
significant advances in our knowledge
of tumor biology, but the treatments
themselves have essentially remained
the same. We use the same type of
treatment for every patient, whether
their disease is newly diagnosed or
metastatic, and we develop clinical
trials using the same unselected
approach. I think it’s time to change.
We need to be able to better select or
stratify patients based on the biological
makeup of their tumor and develop
targeted treatment for every specific
biological group or clinical scenario.
Most of the currently proposed treatment modalities in breast cancer are
modifications of standard chemotherapy
regimens. In my opinion, just changing
the schedule or the dose of administration will not have a significant impact
on outcome for women with breast
cancer. If we do not understand this
fundamental concept and take the
appropriate steps right now, in the
next five years we’ll be in the same
situation.” ●
FOR MORE INFORMATION, contact
Dr. Pusztai or Dr. Cristofanilli at (713)
792-2817 or Dr. Hunt at (713) 792-7216.
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Mind-Body Approaches
for Patients with Cancer

P

opular theories abound about what role the mind plays
in cancer. At one end of the spectrum are those who
claim that cancer develops as a response to stress and
that it can even be cured by the mind. At the other end
are those who believe that a patient’s state of mind has no effect at
all on the outcome of cancer treatment.

Although extremely stressful events
such as the death of a spouse can alter
the function of the body’s immune
system, there is no scientific evidence
that these stress-induced changes in the
immune system cause cancer, according
to the National Cancer Institute. There
is, however, evidence that the mind has
a part to play in the health of the body.
It is not clear exactly how a person’s
mental state affects the cancer process,
but the way a patient copes mentally

and emotionally with the disease is
vitally important. The body processes
controlled by the nervous system can
“plausibly affect resistance to cancer,”
according to an article quoted on M. D.
Anderson Cancer Center’s Complementary/Integrative Medicine Education
Resources (CIMER) Web site
(www.mdanderson.org/cimer). These
processes include a person’s behavior
(for example, adherence to cancer
treatment) as well as the hormonal,

immune, and autonomic nervous
systems. Therefore, comprehensive
medical care “must take into account
not only the biological dimensions of an
illness but also the psychological and
social factors that affect the whole
person,” according to Dr. David Spiegel
in a New England Journal of Medicine
editorial. Dr. Spiegel also wrote,
“Curing cancer may not be a question
of mind over matter, but mind does
matter.”
In fact, several complementary
therapies are mind-body approaches that
help patients manage symptoms, improve
the effectiveness of their treatment, and
increase their overall health and sense of
well-being. These therapies are not cures.
Instead they complement, or add to, the
patient’s medical treatment.

Some common mind-body practices include the following:
■ Support groups
In these groups, patients with
cancer can discuss their feelings
and concerns with other patients.
A support group can meet in person,
online, or via telephone. Some
research indicates that participation
in cancer support groups can reduce
pain and ease distress.
■ Meditation
Meditation comes in many forms,
but most involve concentrating
on one’s breathing or on a visual
experience or silently
repeating a word or
phrase or certain
physical postures or
movements to
release stress and
free the mind
from worries.
For optimal
results, meditation should be
practiced once
or twice a day

for 10 to 20 minutes. The benefits
to patients with cancer can include
diminished pain, reduced stress
hormone levels, improved
immune function,
and improved mood.
■ Hypnosis
Hypnosis is a state
of focused attention. It
is similar to sleep, except
that the patient is alert
and in control but deeply
relaxed and open to suggestion. Hypnosis is usually
performed by a hypnotist, but
people can learn to hypnotize themselves. The American Cancer Society
endorses hypnotherapy for reducing
pain and stress and promoting
relaxation.
■ Yoga
An ancient Hindu practice that
includes breathing exercises, body
postures, and sometimes meditation,
yoga helps patients to relax and gain

control of their bodies and minds.
It also has been shown to relieve pain
and anxiety associated with
cancer and to improve immune
system function.
While these and other mindbody techniques are helpful
for most people, some may be
harmful to specific patients.
Before beginning any complementary therapy, patients should
be sure to check with their
cancer care team. ●

For more information, contact
your physician or contact the
M. D. Anderson Information Line:
(800) 392-1611, Option 3,
✆ within
the United States, or
(713) 792-3245 in Houston
✆ and
outside the United States.
March 2004
©2004 The University of Texas
M. D. Anderson Cancer Center
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Staff Publications
Below is a partial list of staff
publications appearing in March.
Bedrosian I, Lu KH, Verschraegen C,
Keyomarsi K. Cyclin E deregulation alters the biologic properties
of ovarian cancer cells. Oncogene
2004 [e-pub ahead of print].
Carmack Taylor CL, Basen-Engquist
K, Shinn EH, Bodurka DC.
Predictors of sexual functioning
in ovarian cancer patients. J Clin
Oncol 2004;22(5):881-9.
Eifel PJ, Winter K, Morris M,
Levenback C, Grigsby PW,
Cooper J, Rotman M, Gershenson
D, Mutch DG. Pelvic irradiation
with concurrent chemotherapy
versus pelvic and para-aortic
irradiation for high-risk cervical
cancer: an update of radiation
therapy oncology group trial
(RTOG) 90-01. J Clin Oncol
2004;22(5):872-80.
Ellis LM, Hoff PM. Targeting the
epidermal growth factor receptor:
an important incremental step in
the battle against colorectal
cancer. J Clin Oncol 2004 [e-pub
ahead of print].
Fang X, Yu S, Bast RC, Liu S, Xu HJ,
Hu SX, LaPushin R, Claret FX,
Aggarwal BB, Lu Y, Mills GB.
Mechanisms for lysophosphatidic
acid-induced cytokine production
in ovarian cancer cells. J Biol
Chem 2004;279(10):9653-61.
Gomez-Manzano C, Balague C,
Alemany R, Lemoine MG,
Mitlianga P, Jiang H, Khan A,
Alonso M, Lang FF, Conrad CA,
Liu TJ, Bekele BN, Yung WK,
Fueyo J. A novel E1A-E1B
mutant adenovirus induces glioma
regression in vivo. Oncogene
2004;23(10):1821-8.
Herbst RS, Giaccone G, Schiller JH,
Natale RB, Miller V, Manegold C,
Scagliotti G, Rosell R, Oliff I,
Reeves JA, Wolf MK, Krebs AD,
Averbuch SD, Ochs JS, Grous J,

8
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Fandi A, Johnson DH. Gefitinib in
combination with paclitaxel and
carboplatin in advanced nonsmall-cell lung cancer: a phase III
trial—INTACT 2. J Clin Oncol
2004;22(5):785-94.

Discrete gene sets depend on
POU domain transcription
factor Brn3b/Brn-3.2/POU4f2
for their expression in the mouse
embryonic retina. Development
2004;131(6):1197-210.

Issa JP, Garcia-Manero G, Giles FJ,
Mannari R, Thomas D, Faderl S,
Bayar E, Lyons J, Rosenfeld CS,
Cortes J, Kantarjian HM.
Phase 1 study of low-dose
prolonged exposure schedules of
the hypomethylating agent 5-aza2'-deoxycytidine (decitabine) in
hematopoietic malignancies. Blood
2004;103(5):1635-40.

Spurgers KB, Coombes KR, Meyn
RE, Gold DL, Logothetis CJ,
Johnson TJ, McDonnell TJ.
A comprehensive assessment of
p53-responsive genes following
adenoviral-p53 gene transfer
in Bcl-2-expressing prostate
cancer cells. Oncogene
2004;23(9):1712-23.

Ito I, Saeki T, Mohuiddin I, Saito Y,
Branch CD, Vaporciyan A, Roth
JA, Ramesh R. Persistent transgene
expression following intravenous
administration of a liposomal
complex: role of interleukin-10mediated immune suppression. Mol
Ther 2004;9(3):318-27.

Tabe Y, Konopleva M, Munsell MF,
Marini FC, Zompetta C,
McQueen T, Tsao T, Zhao S,
Pierce S, Igari J, Estey EH,
Andreeff M. PML-RARα is
associated with leptin-receptor
induction: the role of mesenchymal stem cell–derived adipocytes in APL cell survival.
Blood 2004;103(5):1815-22.

Kleymenova E, Everitt JI, Pluta L,
Portis M, Gnarra JR, Walker CL.
Susceptibility to vascular
neoplasms but no increased
susceptibility to renal carcinogenesis in Vhl knockout mice.
Carcinogenesis 2004;25(3):309-15.
Lee CM, Lo HW, Shao RP, Wang SC,
Xia W, Gershenson DM, Hung
MC. Selective activation of
ceruloplasmin promoter in ovarian
tumors: potential use
for gene therapy. Cancer Res
2004;64(5):1788-93.
Liu J, Yang G, Thompson-Lanza JA,
Glassman A, Hayes K, Patterson
A, Marquez RT, Auersperg N, Yu
Y, Hahn WC, Mills GB, Bast RC
Jr. A genetically defined model for
human ovarian cancer. Cancer Res
2004;64(5):1655-63.
Makino K, Day CP, Wang SC, Li YM,
Hung MC. Upregulation of
IKK-α/IKK-β by integrinlinked kinase is required for
HER2/neu-induced NF-kappaB
antiapoptotic pathway. Oncogene
2004 [e-pub ahead of print].

Wong R, Durand JB, Luna MA,
Couriel DR, Gajewski JL.
Images in cardiovascular
medicine. Constrictive
pericarditis in a patient with
relapsed acute myelogenous
leukemia after allogeneic bone
marrow transplantation.
Circulation 2004;109(9):e146-9.
Yan C, Wang H, Aggarwal B,
Boyd DD. A novel homologous
recombination system to study
92 kDa type IV collagenase
transcription demonstrates that
the NF-kappaB motif drives the
transition from a repressed to
an activated state of gene
expression. FASEB J
2004;18(3):540-1.
Youssef EM, Lotan D, Issa JP,
Wakasa K, Fan YH, Mao L,
Hassan K, Feng L, Lee JJ,
Lippman SM, Hong WK, Lotan
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